Table 2.
Microbiological outcomes, by time period and prophylaxis regimen.
| Variable | 2003–2007 | 2008–2012 | 2013–2017 |
|---|---|---|---|
| PBx procedures performed, n | 2218 | 2798 | 3957 |
| Blood cultures obtained, n/N (%) | 28/2218 (1.3) | 56/2798 (2.0) | 120/3957 (3.0) |
| Rate of positive blood cultures | 9/2218 (0.4) | 24/2798 (0.9) | 55/3957 (1.4) |
| Proportion with positive finding | 9/28 (32) | 24/56 (43) | 55/120 (46) |
| Urine cultures obtained, n/N (%) | 141/2218 (6.4) | 98/2798 (3.5) | 189/3957 (4.8) |
| Rate of positive urine cultures | 31/2218 (1.4) | 40/2798 (1.4) | 88/3957 (2.2) |
| Proportion with positive finding | 31/141 (22) | 40/98 (41) | 88/189 (47) |
| Rate of blood and/or urine positivity, n/N (%) | 33/2218 (1.5) | 51/2798 (1.8) | 103/3957 (2.6) |
| In group receiving single‐dose ciprofloxacin | 27/1865 (1.4) | 44/2325 (1.9) | 77/2951 (2.6) |
| In group receiving prolonged ciprofloxacin | 4/282 (1.4) | 5/439 (1.1) | 23/942 (2.4) |
| In group receiving other prophylaxis | 1/38 (3) | 2/30 (7) | 3/64 (5) |
| Proportion with ciprofloxacin resistance, n/N (%) | 17/33 (52) | 22/51 (43) | 45/103 (44) |
| In group receiving single‐dose ciprofloxacin | 13/27 (48) | 21/44 (48) | 31/77 (40) |
| In group receiving prolonged ciprofloxacin | 3/4 (75) | 1/5 (20) | 12/23 (52) |
| In group receiving other prophylaxis | 0/1 | 0/2 | 2/3 (67) |
| Proportion with EPE, n/N (%) | 2/33 (6) | 6/51 (12) | 14/103 (14) |
| In group receiving single‐dose ciprofloxacin | 2/27 (7) | 6/44 (14) | 8/77 (10) |
| In group receiving prolonged ciprofloxacin | 0/4 | 0/5 | 4/23 (17) |
| In group receiving other prophylaxis | 0/1 | 0/2 | 2/3 (67) |